A Comparative study of different treatment regimes for brain tuberculosis

A Comparative study comparing intensified treatment with Moxifloxacin/Pyrazinamide versus standard Anti-tubercular therapy for CNS Tuberculoma

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/05/019222

Enrollment

Registered

2019-05-20

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A171- Meningeal tuberculoma

Interventions

Intervention1: Moxifloxacin/Pyrazinamide VS standard antitubercular therapy: Group B- 5-drug ATT: INH, Rifampicin, Pyrazinamide, Ethambutol and Moxifloxacin in the 1st 2 months of Intensive phase fol

Eligibility

Inclusion criteria

Inclusion criteria: Clinically and radiologically suspected cases of CNS tuberculoma

Exclusion criteria

Exclusion criteria: <18yrs, pregnant, HIV positive,refusal to participate in the study

Design outcomes

Primary

Measure	Time frame
Reduction in size/disappearance of TuberculomaTimepoint: 3 months, 6 months, 12 months, 18 months	—

Secondary

Measure	Time frame
Improvement in clinical parameters,symptoms and signs like headache,focal deficits and reduction in disability scores. Timepoint: 3 months, 6 months, 12 months, 18 months	—

Countries

India

Contacts

Public ContactDr Nalini Atchayaram

National Institute of Mental Health and Neurosciences

atchayaramnalini@yahoo.co.in9632505634

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026